

Lahiru Handunnetthi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6339682/publications.pdf>

Version: 2024-02-01

38
papers

3,228
citations

361413

20
h-index

315739

38
g-index

45
all docs

45
docs citations

45
times ranked

4893
citing authors

#	ARTICLE	IF	CITATIONS
1	A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. <i>Genome Research</i> , 2010, 20, 1352-1360.	5.5	737
2	Expression of the Multiple Sclerosis-Associated MHC Class II Allele HLA-DRB1*1501 Is Regulated by Vitamin D. <i>PLoS Genetics</i> , 2009, 5, e1000369.	3.5	442
3	Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. <i>Nature Medicine</i> , 2022, 28, 410-422.	30.7	392
4	An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis. <i>PLoS ONE</i> , 2010, 5, e12496.	2.5	260
5	Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2144-2153.	30.7	249
6	A genetics-led approach defines the drug target landscape of 30 immune-related traits. <i>Nature Genetics</i> , 2019, 51, 1082-1091.	21.4	157
7	Regulation of major histocompatibility complex class II gene expression, genetic variation and disease. <i>Genes and Immunity</i> , 2010, 11, 99-112.	4.1	122
8	Prodromal symptoms of multiple sclerosis in primary care. <i>Annals of Neurology</i> , 2018, 83, 1162-1173.	5.3	98
9	Perceptual Systems Controlling Speech Production. <i>Journal of Neuroscience</i> , 2008, 28, 9969-9975.	3.6	91
10	Multiple sclerosis, vitamin D, and HLA-DRB1*15. <i>Neurology</i> , 2010, 74, 1905-1910.	1.1	85
11	Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. <i>Journal of the Neurological Sciences</i> , 2011, 305, 116-120.	0.6	61
12	Heterogeneity in Multiple Sclerosis: Scratching the Surface of a Complex Disease. <i>Autoimmune Diseases</i> , 2011, 2011, 1-12.	0.6	55
13	Genetic and environmental factors and the distribution of multiple sclerosis in Europe. <i>European Journal of Neurology</i> , 2010, 17, 1210-1214.	3.3	52
14	The emerging role of vitamin D binding protein in multiple sclerosis. <i>Journal of Neurology</i> , 2011, 258, 353-358.	3.6	43
15	Prevalence of primary outcome changes in clinical trials registered on ClinicalTrials.gov: a cross-sectional study. <i>F1000Research</i> , 2014, 3, 77.	1.6	40
16	Type 1 diabetes mellitus and multiple sclerosis: common etiological features. <i>Nature Reviews Endocrinology</i> , 2009, 5, 655-664.	9.6	34
17	The Effect of Single Nucleotide Polymorphisms from Genome Wide Association Studies in Multiple Sclerosis on Gene Expression. <i>PLoS ONE</i> , 2010, 5, e10142.	2.5	32
18	No evidence for an effect of DNA methylation on multiple sclerosis severity at HLA-DRB1*15 or HLA-DRB5. <i>Journal of Neuroimmunology</i> , 2010, 223, 120-123.	2.3	25

#	ARTICLE	IF	CITATIONS
19	A genome-wide scan of male sexual orientation. <i>Journal of Human Genetics</i> , 2010, 55, 131-132.	2.3	25
20	DNase hypersensitive sites and association with multiple sclerosis. <i>Human Molecular Genetics</i> , 2014, 23, 942-948.	2.9	21
21	Parent-of-origin of HLA-DRB1*1501 and age of onset of multiple sclerosis. <i>Journal of Human Genetics</i> , 2009, 54, 547-549.	2.3	19
22	Methylation of class II transactivator gene promoter IV is not associated with susceptibility to Multiple Sclerosis. <i>BMC Medical Genetics</i> , 2008, 9, 63.	2.1	18
23	Season of birth and anorexia nervosa. <i>British Journal of Psychiatry</i> , 2011, 198, 404-405.	2.8	18
24	Funding source and primary outcome changes in clinical trials registered on ClinicalTrials.gov are associated with the reporting of a statistically significant primary outcome: a cross-sectional study. <i>F1000Research</i> , 2015, 4, 80.	1.6	17
25	Contribution of genetic, epigenetic and transcriptomic differences to twin discordance in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1379-1381.	2.8	15
26	Funding source and primary outcome changes in clinical trials registered on ClinicalTrials.gov are associated with the reporting of a statistically significant primary outcome: a cross-sectional study. <i>F1000Research</i> , 2015, 4, 80.	1.6	15
27	Global proteomic analysis of extracellular matrix in mouse and human brain highlights relevance to cerebrovascular disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2423-2438.	4.3	14
28	Maternal infection in gestation increases the risk of non-affective psychosis in offspring: a meta-analysis. <i>Journal of Psychiatric Research</i> , 2021, 139, 125-131.	3.1	11
29	Maternal immune activation downregulates schizophrenia genes in the foetal mouse brain. <i>Brain Communications</i> , 2021, 3, fcab275.	3.3	10
30	Revisiting the T-cell receptor alpha/delta locus and possible associations with multiple sclerosis. <i>Genes and Immunity</i> , 2011, 12, 59-66.	4.1	9
31	Genomic Insights into Myasthenia Gravis Identify Distinct Immunological Mechanisms in Early and Late Onset Disease. <i>Annals of Neurology</i> , 2021, 90, 455-463.	5.3	8
32	UV radiation, vitamin D, and multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, E130; author reply E131.	7.1	7
33	Integrating multiple oestrogen receptor alpha ChIP studies: overlap with disease susceptibility regions, DNase I hypersensitivity peaks and gene expression. <i>BMC Medical Genomics</i> , 2013, 6, 45.	1.5	7
34	Regulatory genomic regions active in immune cell types explain a large proportion of the genetic risk of multiple sclerosis. <i>Journal of Human Genetics</i> , 2014, 59, 211-215.	2.3	6
35	Parental non-inherited HLA resistance alleles do not confer protection against multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2008, 196, 170-172.	2.3	3
36	The role of latitude and infections in the month-of-birth effect linked to schizophrenia. <i>Brain, Behavior, & Immunity - Health</i> , 2022, 24, 100486.	2.5	2

#	ARTICLE	IF	CITATIONS
37	Variants in ST8SIA1 do not play a major role in susceptibility to multiple sclerosis in Canadian families. Journal of Neuroimmunology, 2009, 212, 142-144.	2.3	1
38	Association Between Maternal Height and Childhood Outcomes. JAMA - Journal of the American Medical Association, 2010, 304, 638.	7.4	0